

GALCANEZUMAB injection (Emgality® ▼) for prevention of migraine

The Pan Mersey Area Prescribing Committee recommends the prescribing of GALCANEZUMAB injection (Emgality® ▼), by specialists only, for prevention of migraine in accordance with NICE TA659.

RED

Galcanezumab is licensed for prophylaxis of migraine in adults who have at least 4 migraine days per month.^[1]

[NICE technology appraisal \(TA\) 659](#)^[2] (18 November 2020) recommends galcanezumab (Emgality® ▼) as an option for preventing migraine in adults, only if:

- > they have 4 or more migraine days a month
- > at least 3 preventative drug treatments have failed and
- > the company provides it according to the commercial arrangement.

Treatment should be initiated by a specialist experienced in the diagnosis and treatment of migraine. Prescribing should be retained by the specialist.

Galcanezumab should be stopped after 12 weeks of treatment if:

- > in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50%
- > in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.^[2]

For further information on the prevention of migraine, please refer to the following national and local guidance:

- > NICE Clinical Guideline [CG150] [Headaches in over 12s: diagnosis and management](#), updated November 2015.
- > British Association for the Study of Headache [National Headache Management System for Adults](#), 2019.
- > Pan Mersey Area Prescribing Committee [Headache pathway \(adults\)](#), last updated 30 July 2020.

NICE estimates the resource impact of implementing this guidance to be £8,000 per 100,000 population in 2020/21, rising to £34,000 per 100,000 population in 2024/25, at which point NICE assumes steady state to have been reached.

References

1. Eli Lilly and Company Limited. Summary of Product Characteristics: [Emgality 120mg solution for injection in pre-filled pen](#), 26 March 2020. Accessed 27 November 2020.
2. National Institute for Health and Care Excellence. Technology appraisal 659; [Galcanezumab for preventing migraine](#), 18 November 2020. Accessed 27 November 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.